Caplin Point Laboratories Ltd. benchmarking: Perfomance to industry peers

Financial

	Caplin Point Lab	Gufic Biosciences	Gland Pharma
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	51.0 .	n/a	372.0 .
Number of ANDA's Approved By USFDA	38.0 .	n/a	325.0 .
R&D as a % of Total Sales	3.52 %	1.28 %	4.4 %
Financials
5 yr Average ROE	19.84 %	16.89 %	12.02 %
5yr average Equity Multiplier	1.15	2.16	1.15
5yr Average Asset Turnover Ratio	0.68	0.75	0.51
5yr Avg Net Profit Margin	25.35 %	10.24 %	20.79 %
Price to Book	5.35	5.47	3.4
P/E	26.98	53.1	42.18
5yr Avg Cash Conversion Cycle	70.68 Days	-15.25 Days	69.81 Days
Inventory Days	66.07 Days	71.73 Days	118.26 Days
Days Receivable	110.7 Days	106.89 Days	99.92 Days
Days Payable	85.23 Days	179.29 Days	107.43 Days
5yr Average Interest Coverage Ratio	633.04	8.9	183.05
5yr Avg ROCE	24.45 %	17.89 %	16.55 %
5yr Avg Operating Profit Margin	31.52 %	18.12 %	29.26 %
5 yr average Debt to Equity	0.0	0.67	0.01
5yr CAGR Net Profit	17.23 %	-2.66 %	-6.87 %
5yr Average Return on Assets	17.23 %	7.7 %	10.65 %
Shareholdings
Promoter Holding	70.57 %	72.5 %	51.83 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	1.69 %	-2.5 %	-6.03 %
Change in Mutual Fund Holding (3 Yrs)	0.74 %	2.45 %	11.71 %

Business

	Caplin Point Lab	Gufic Biosciences	Gland Pharma
Product Wise Break-Up	Product Wise Break-Up Formulations 75.0 Branded Generics 25.0 API 0 Muscle Relaxants 0 Cardiovascular 0 Proton pump inhibitors 0 Anti-fungals 0 Anti-bacterials 0 International 0 CMO 0 Domestic 0 Injectables 0 Pharmaceuticals 0	Product Wise Break-Up Anti-bacterials 0 International 15.0 CMO 30.0 Anti-fungals 0 Cardiovascular 0 Domestic Pharmaceuticals 50.0 Branded Generics 0 Pharmaceuticals 0 Proton pump inhibitors 0 Active Pharmaceutical Ingredient (API) 5.0 Muscle Relaxants 0 Injectables 0 Formulations 0	Product Wise Break-Up Anti-bacterials 0 International 0 CMO 0 Anti-fungals 0 Cardiovascular 0 Domestic 0 Branded Generics 0 Pharmaceutical 100.0 Proton pump inhibitors 0 API 0 Muscle Relaxants 0 Injectables 0 Formulations 0
Location Wise Break-Up	Location Wise Break-Up Latin America 76.0 USA 18.0 Africa 6.0 India 0 South America 0 Australia 0 North America 0 Europe 0 Asia 0 Rest of the World 0 Canada, Australia & New Zealand 0 Canada 0	Location Wise Break-Up Latin America 0 Asia Pacific 6.04 Rest of the World 0 Europe 7.54 Canada, Australia & New Zealand 0 North America 1.19 Africa 2.95 USA 0 South America 2.37 Australia 0.08 Canada 0 India 79.83	Location Wise Break-Up Latin America 0 Asia 0 Rest of the World 0 Europe 6.14 Canada, Australia & New Zealand 4.54 North America 0 Africa 0 USA 68.88 South America 0 Australia 0 Canada 0 India 5.71 Others 14.73
Distribution Channel	Distribution Channel Distribution 45.0 Pharmacy and Dietary 35.0 Tender Business 20.0 B2C 0 B2B 0	-	Distribution Channel Tender Business 0 Pharmacy and Dietary 0 B2B 99.0 B2C 1.0 Distribution 0
Manufacturing Break-Up	Manufacturing Break-Up India 73.0 China 27.0	-	-

Caplin Point Laboratories Ltd.

Caplin Point Laboratories Ltd.

Financial

Business

SIGN UP FOR FREE